CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

Tolvaptan Samsca 2181 A Sgm P2024

Defines coverage criteria for Samsca (tolvaptan) including FDA-approved indication for clinically significant hypervolemic and euvolemic hyponatremia and limits (hospital initiation, serum sodium thresholds, 30-day authorization). Declares all other indications experimental/investigational and not medically necessary.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

PolicyTolvaptan Samsca 2181 A Sgm P2024

Policy CodePolicy N/A

Change TypeNo material changes

Effective Date

Next Review Date

Key ActionAuthorization of up to 30 days may be granted when all criteria are met; therapy must have been initiated or re-initiated in the hospital and member must meet serum sodium criteria.

SourceLink

POLICY UPDATE CHANGES

No material changes

1Covered Indication (primary)

30dInitial Authorization Duration

2Serum Sodium Thresholds Specified

Coverage Summary & Scope

Coverage stance: Covered with criteria for FDA-approved clinically significant hypervolemic and euvolemic hyponatremia. Scope: policy applies to Samsca (tolvaptan) for patients meeting the FDA indication (including heart failure and SIADH) and requires hospital initiation, specific serum sodium thresholds, and documentation. High-level limits: therapy must be initiated in the hospital, initial authorization is limited to 30 days, and use for urgent neurologic correction to rapidly raise serum sodium is explicitly excluded.

Initial Therapy Criteria (Authorization — up to 30 days)

Covered Indication: Hypervolemic/Euvolemic Hyponatremia

Authorization of 30 days may be granted when ALL of the following criteria are met:

ALL of the following

Hospital initiation: Therapy was initiated (or re-initiated) in the hospital for hypervolemic or euvolemic hyponatremia.
Serum sodium at initiation: Serum sodium was less than 125 mEq/L OR serum sodium was less than 135 mEq/L with symptoms (e.g., nausea, vomiting, headache, lethargy, confusion) at the time of therapy initiation.Serum sodium: <125 mEq/L; or <135 mEq/L with symptoms
Treatment duration limit: The member will not receive the requested drug continually for greater than 30 days.<= 30 days

General FDA-Approved Indication

Covered when ALL of the following general conditions apply:

ALL of the following

FDA-approved indication: Indication is treatment of clinically significant hypervolemic and euvolemic hyponatremia (serum sodium <125 mEq/L or less marked hyponatremia that is symptomatic and has resisted correction with fluid restriction), including patients with heart failure and SIADH.Serum sodium: <125 mEq/L; or less marked symptomatic hyponatremia resistant to fluid restriction
No exclusions: Member has no exclusions to the prescribed therapy.

Continuation Therapy Criteria

Initial authorization is limited to 30 days when all criteria are met (hospital initiation, qualifying serum sodium level or symptomatic hyponatremia). The policy requires that the member will not receive the drug continuously for greater than 30 days, implying therapy should not be continued beyond that initial period without meeting additional criteria.

Provider Actions & Billing Impact

Prior Authorization

Authorization required for 30 days

Authorization of up to 30 days may be granted when all criteria are met; therapy must have been initiated or re-initiated in the hospital and member must meet serum sodium criteria.

Documentation Required

Document hospital initiation and serum sodium

Document that therapy was initiated (or re-initiated) in the hospital and record serum sodium values and symptom status at the time of initiation.

Denial Risk

Denial for non-FDA indications

Claims for indications other than FDA‑approved hypervolemic/euvolemic hyponatremia or compendial uses are considered experimental/investigational and not medically necessary and may be denied.

Denial Risk

Denial for urgent neurologic correction use

Do not use Samsca/tolvaptan for patients requiring urgent intervention to raise serum sodium to prevent or treat serious neurological symptoms; this use is contraindicated and will not meet coverage criteria.

Clinical Evidence & References

Evidence references:

• Samsca [package insert], Otsuka America Pharmaceutical, Inc.; April 2021.

• Tolvaptan [package insert], Novadoz Pharmaceuticals LLC; March 2023.

• Hoorn EJ, Zietse R. Diagnosis and treatment of hyponatremia: Compilation of the guidelines. J Am Soc Nephrol. 2017;28(5):1340-1349.

Background & Definitions

Samsca (tolvaptan) is approved for treatment of clinically significant hypervolemic and euvolemic hyponatremia (including heart failure and SIADH). The policy emphasizes that therapy must be initiated in the hospital, that initial authorization is limited to 30 days, and that Samsca/tolvaptan should not be used for patients requiring urgent neurologic correction to rapidly raise serum sodium.

Hypervolemic/Euvolemic Hyponatremia: Clinical hyponatremia states addressed by the FDA indication for tolvaptan; policy applies when serum sodium thresholds and symptom criteria are met (e.g., serum sodium <125 mEq/L, or <135 mEq/L with symptoms).